The role of stem cell factor and c-KIT in keloid pathogenesis: Do tyrosine kinase inhibitors have a potential therapeutic role?

British Journal of Dermatology

Volumn 164, Issue 2, 2011, Pages 372-386

  Mukhopadhyay, A ^a   Do, D V ^a   Ong, C T ^a   Khoo, Y T ^a   Masilamani, J ^a   Chan, S Y ^a   Vincent, A S ^a   Wong, P K ^a   Lim, C P ^c   Cao, X ^c   Lim, I J ^a   Phan, T T ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; STEM CELL FACTOR;

ARTICLE; CELL CULTURE; CELL INTERACTION; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KELOID; KERATINOCYTE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; WOUND HEALING;

BLOTTING, WESTERN; CELL COMMUNICATION; CELLS, CULTURED; COCULTURE TECHNIQUES; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; KELOID; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; SKIN; STEM CELL FACTOR; UP-REGULATION;

EID: 79551496151     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10035.x     Document Type: Article

References (73)

1. Clark RA, ed. The Molecular and Cellular Biology of Wound Repair, 2nd edn. New York: Plenum, 1996; 3-50.
2. Ladin D, Garner WL, Smith DS Jr,. Excessive scarring as a consequence of healing. Wound Repair Regen 1995; 3: 6-14.
3. Ala-Kokko L, Rintala A, Savolainen ER,. Collagen gene expression in keloids: analysis of collagen metabolism and type I, III, IV and V procollagen mRNAs in keloid tissue and keloid fibroblast cultures. J Invest Dermatol 1987; 89: 238-44.
4. Di Cesare PE, Cheung DT, Perelman N, et al. Alteration of collagen composition and cross-linking in keloid tissues. Matrix 1990; 10: 172-8.
5. Tuan TL, Nitcher LS,. The molecular basis of keloid and hypertrophic scar formation. Mol Med Today 1998; 4: 19-24.
6. Niessen FB, Spauwen PHM, Schalkwijk J, Kon M,. On the nature of hypertrophic scars and keloids. Plast Reconstr Surg 1999; 104: 1435-58.
7. Kim WJH, Levinson H, Gittes GK, Longaker MT,. In: Scarless Wound Healing (, Garg HG, Longaker MT, eds). New York: Marcel Dekker Inc., 2000; 161-71.
8. Ong CT, Khoo YT, Tan EK, et al. Epithelial-mesenchymal interactions in keloid pathogenesis modulate vascular growth factor expression and secretion. J Pathol 2007; 211: 95-108.
9. Khoo YT, Ong CT, Mukhopadhyay A, et al. Upregulation of secretory connective tissue growth factor in keratinocyte-fibroblast coculture contributes to keloid pathogenesis. J Cell Physiol 2006; 208: 336-43.
10. Mukhopadhyay A, Chan SY, Lim IJ, et al. The role of the activin system in keloid pathogenesis. Am J Physiol Cell Physiol 2007; 292: C1331-8.
11. Yoshimoto H, Ishihara H, Ohtsuru A,. Overexpression of insulin-like growth factor-1 (IGF-1) receptor and the invasiveness of cultured keloid fibroblasts. Am J Pathol 1999; 154: 883-9.
12. Xue H, McCauley RL, Zhang W,. Elevated interleukin-6 expression in keloid fibroblasts. J Surg Res 2000; 89: 74-7.
13. Gabrilove JL, White K, Rahman Z, Wilson EL,. Stem cell factor and basic fibroblast growth factor are synergistic in augmenting committed myeloid progenitor cell growth. Blood 1994; 83: 907-10.
14. Ashman LK,. The biology of stem cell factor and its receptor c-KIT. Int J Biochem Cell Biol 1999; 31: 1037-51.
15. Broudy VC,. Stem cell factor and hematopoiesis. Blood 1997; 90: 1345-64.
16. Lyman SD, Jacobsen SE,. c-KIT ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998; 91: 1101-34.
17. Yarden Y, Kuang WJ, Yang-Feng T, et al. Homo proto-oncogene c-KIT: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987; 6: 3341-51.
18. Natali PG, Nicotra MR, Sures I, et al. Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res 1992; 52: 6139-43.
19. Lammie A, Drobnjak M, Gerald W, et al. Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem 1994; 42: 1417-25.
20. Williams DE, Eisenman J, Baird A, et al. Identification of a ligand for the c-KIT proto-oncogene. Cell 1990; 63: 167-74.
21. Mayrhofer G, Gadd SJ, Spargo LD, Ashman LK,. Specificity of a mouse monoclonal raised acute myeloid leukemia cells for mast cells in human mucosal and connective tissues. Immunol Cell Biol 1987; 65: 241-50.
22. Majumder S, Brown K, Qiu FH, Besmer P,. c-Kit protein, a transmembrane kinase: identification in tissues and characterization. Mol Cell Biol 1998; 8: 4896-903.
23. Nocka K, Majumder S, Chabot B, et al. Expression of c-KIT gene products in known cellular targets of W mutations in normal and W mutant mice-evidence for an impaired c-KIT kinase in mutant mice. Genes Dev 1989; 3: 816-26.
24. Wang C, Curtis JE, Geissler EN, et al. The expression of the proto-oncogene c-KIT in the blast cells of acute myeloblastic leukemia. Leukemia 1989; 3: 699-702.
25. Broudy VC, Kovach NL, Bennett LG, et al. Human umbilical vein endothelial cells display high-affinity c-kit receptors and produce a soluble form of the c-kit receptor. Blood 1994; 83: 2145-52.
26. Blume-Jensen P, Claesson-Welsh L, Siegbahn A, et al. Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis. EMBO J 1991; 10: 4121-8.
27. Huang E, Nocka K, Beier DR, et al. The hematopoietic growth factor KL is encoded by the SI locus and is the ligand of the c-KIT receptor, the gene product of the W locus. Cell 1990; 63: 225-33.
28. Zsebo KM, Williams DA, Geissler EN, et al. Stem cell factor is encoded at the S1 locus of the mouse and is the ligand for the c-KIT tyrosine kinase receptor. Cell 1990; 63: 213-24.
29. Garbuzenko E, Nagler A, Pickholtz D, et al. Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: a direct role for mast cells in skin fibrosis. Clin Exp Allergy 2002; 32: 237-46.
30. Fireman E, Kivity S, Shahar I, et al. Secretion of stem cell factor by alveolar fibroblasts in interstitial lung diseases. Immunol Lett 1999; 67: 229-36.
31. El Kossi MM, El Nahas AM,. Stem cell factor and crescentic glomerulonephritis. Am J Kidney Dis 2003; 41: 785-95.
32. Krystal GW, Hines SJ, Organ CP,. Autocrine growth of small cell lung cancer mediated by coexpression of c-KIT and stem cell factor. Cancer Res 1996; 56: 370-6.
33. Hibi K, Takahashi T, Sekido Y, et al. Coexpression of the stem cell factor and c-KIT genes in small-cell lung cancer. Oncogene 1991; 6: 2291-6.
34. Iyer VR, Eisen MB, Ross DT, et al. The transcriptional program in the response of human fibroblasts to serum. Science 1999; 283: 83-7.
35. Vincent AS, Lim BG, Tan J,. Sulfite-mediated oxidative stress in kidney cells. Kidney Int 2004; 65: 393-402.
36. Zhang X, Vincent AS, Halliwell B, Wong KP,. A mechanism of sulphite neurotoxicity: direct inhibition of glutamate dehydrogenase. J Biol Chem 2004; 279: 43035-45.
37. Ng LE, Vincent AS, Halliwell B, Wong KP,. Action of diclofenac on kidney mitochondria and cells. Biochem Biophys Res Commun 2006; 348: 494-500.
38. Bradford MM,. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
39. Cohen IK, Peacock EE,. Keloids and hypertrophic scars in plastic surgery. In: Plastic Surgery (, McCarthy JG, ed). Philadelphia: Saunders, 1990; 732-47.
40. Sayah DN, Chia S, Shaw WW, et al. Down-regulation of apoptosis-related genes in keloid tissues. J Surg Res 1999; 87: 209-16.
41. Chodon T, Sugihara T, Igawa H, et al. Keloid-derived fibroblasts are refractory to Fas-mediated apoptosis and neutralization of autocrine transforming growth factor-β1 can abrogate this resistance. Am J Pathol 2000; 157: 1661-9.
42. Lewis TS, Shapiro PS, Ahn NG,. Vascular endothelial growth factor is a secreted angiogenic mitogen. Adv Cancer Res 1998; 74: 49-139.
43. Thommes K, Lennartsson J, Carlberg M, Ronnstrand L,. Identification of Tyr-703 and Tyr-936 as the primary association sites for GRb2 and GRb7 in the c-KIT stem cell factor receptor. Biochem J 1999; 341: 211-16.
44. Yee NS, Langen H, Besmer P,. Mechanism of kit ligand, phorbol ester, and calcium induced down regulation of c-KIT receptors in mast cells. J Biol Chem 1993; 268: 14189-201.
45. Timokhina I, Kissel H, Stella G, Besmer P,. Kit signaling through PI3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation. EMBO J 1998; 17: 6250-62.
46. Serve H, Yee NS, Stella G, et al. Differential roles of PI3-kinase and kit tyrosine 821 in kit receptor-mediated proliferation, survival and cell adhesion in mast cells. EMBO J 1995; 14: 473-83.
47. Kubota Y, Angelotti T, Niederfellner G, et al. Activation of phosphatidylinositol 3-kinase is necessary for differentiation of FDC-P1 cells following stimulation of type III receptor tyrosine kinases. Cell Growth Differ 1998; 9: 247-56.
48. Vosseller K, Stella G, Yee NS, Besmer P,. c-KIT receptor signaling through its phosphatidylinositide-3′-kinase-binding site and protein kinase C: role in mast cell enhancement of degranulation, adhesion, and membrane ruffling. Mol Biol Cell 1997; 8: 909-22.
49. Huttunen M, Naukkarinen A, Horsmanheimo N, Harvima IT,. Transient production of stem cell factor in dermal cells but increasing expression of Kit receptor in mast cells during normal wound healing. Arch Dermatol Res 2002; 294: 324-30.
50. Lim IJ, Phan TT, Song C, et al. Investigation of the influence of keloid-derived keratinocytes on fibroblast growth and proliferation in vitro. Plast Reconstr Surg 2001; 107: 797-808.
51. Lim IJ, Phan TT, Bay BH, et al. Fibroblasts co-cultured with keloid keratinocytes: normal fibroblasts secrete collagen in keloid like manner. Am J Physiol Cell Physiol 2002; 283: C212-22.
52. Chesneau V, Becherer JD, Zheng Y, et al. Catalytic properties of ADAM19. J Biol Chem 2003; 278: 22331-40.
53. Zou J, Zhu F, Liu J, et al. Catalytic activity of human ADAM33. J Biol Chem 2004; 279: 9818-30.
54. Hessig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002; 109: 625-37.
55. Da Silva CA, Kassel O, Mathieu E, et al. Inhibition by glucocorticoids of the interleukin-1beta-enhanced expression of the mast cell growth factor SCF. Br J Pharmacol 2002; 135: 1634-40.
56. Ren X, Hogaboam C, Carpenter A, Colletti L,. Stem cell factor restores hepatocyte proliferation in IL-6 knockout mice following 70% hepatectomy. J Clin Invest 2003; 112: 1407-18.
57. Cruz AC, Frank BT, Edwards ST, et al. Tumor necrosis factor-alpha converting enzyme controls surface expression of c-KIT and survival of embryonic stem cell-derived mast cells. J Biol Cell 2004; 279: 5612-20.
58. Yee NS, Hsiau CW, Serve H, et al. Mechanism of down-regulation of c-KIT receptor tyrosine kinase, phosphatidylinositol 3′-kinase, and protein kinase C. J Biol Chem 1994; 269: 31991-8.
59. Miyazawa K, Toyama K, Gotoh A, et al. Ligand-dependent polyubiquitination of c-kit gene product: a possible mechanism of receptor down modulation in M07e cells. Blood 1994; 83: 137-45.
60. Brizzi MF, Blechman JM, Cavalloni G, et al. Protein kinase C-dependent release of a functional whole extracellular domain of the mast cell growth factor (MGF) receptor by MGF-dependent human myeloid cells. Oncogene 1994; 9: 1583-9.
61. Tajima F, Kawatani T, Ishiga K, et al. Serum soluble c-KIT receptor and expression of c-KIT protein and mRNA in acute myeloid leukemia. Eur J Haematol 1998; 60: 289-96.
62. Kawakita M, Yonemura Y, Miyake H, et al. Soluble c-kit molecule in serum from healthy individuals and patients with haemopoietic disorders. Br J Haematol 1995; 91: 23-9.
63. Peters M, Jacobs S, Ehlers M, et al. The function of the soluble interleukin 6 receptor in vivo: sensitization of human soluble IL-8 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 1996; 183: 1399-406.
64. Heaney ML, Golde DW,. Soluble cytokine receptors. Blood 1996; 87: 847-57.
65. Capdeville R, Buchdunger E, Zimmermann J, Matter A,. Glivec (ST1571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493-503.
66. Sattler M, Salgia R,. Targeting c-KIT mutations. Basic science to novel therapies. Leuk Res 2004; 28: S11-20.
67. Aono Y, Nishioka Y, Inayama M, et al. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2005; 171: 1279-85.
68. Wang S, Wilkes MC, Leof EB, Hirschberg R,. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J 2005; 19: 1-11.
69. Xia W, Phan TT, Lim IJ, et al. Complex epithelial-mesenchymal interactions modulate transforming growth factor-β expression in keloid-derived cells. Wound Repair Regen 2004; 12: 546-56.
70. Mori M, Morishita H, Nakamura H, et al. Hepatoma-derived growth factor is involved in lung remodeling by stimulating epithelial growth. Am J Respir Cell Mol Biol 2004; 30: 459-69.
71. Yu C, Wang F, Jin C, et al. Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis. Am J Pathol 2003; 163: 1653-62.
72. Bell E, Ivarsson B, Merrill C,. Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potentials in vitro. Proc Natl Acad Sci USA 1979; 76: 1274-8.
73. Ueda K, Furuya E, Yasuda Y, et al. Keloids have continuous high metabolic activity. Plast Reconstr Surg 1999; 104: 694-8.